POM-V Prescription Required

CIDR 1.38 g Vaginal Delivery System for Cattle

Active ingredient: Progesterone

Form

Vaginal delivery system

Species

Cattle

Manufacturer

Zoetis Belgium S.A.

VMD MA No.

60021/3040

What it's used for

Synchronisation of donor and recipient animals for embryo transfer. To be used in combination with prostaglandin F2  Use as recommended, normally results...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Progesterone

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

CIDR 1.38 g Vaginal Delivery System for Cattle — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Synchronisation of donor and recipient animals for embryo transfer.
To be used in combination with prostaglandin F2 
Use as recommended, normally results in oestrus 48-96 hours after device removal
with the majority of animals showing oestrus within 48-72 hours.
For induction and synchronisation of oestrus in Fixed Time Artificial Insemination
(FTAI) protocols:
In cycling cows and heifers. To be used in combination with prostaglandin F2 
(PGF2α) or analogue.
AN: 03122/2024Page 2 of 8
In cycling and non-cycling cows and heifers. To be used in combination with
Gonadotrophin releasing hormone (GnRH) or analogue and PGF2α or analogue.
In non-cycling cattle. To be used in combination with PGF2α or analogue and equine
chorionic gonadotrophin (eCG).

For synchronisation of oestrus and synchronisation of donor and recipient animals for
embryo transfer:
One device should be inserted into the vagina of each cow or heifer to be treated. The
vaginal insert should be left in position for 7 days with an injection of a luteolytic dose of
prostaglandin F2
respond to treatment the onset of oestrus generally occurs within 1-3 days after
removal of the insert. Cows should be inseminated within 12 hours of first observed
oestrus.
For the induction and synchronisation of oestrus for Fixed Time Artificial Insemination
(FTAI):
The following FTAI protocols have been commonly reported in the scientific literature
and should be used:
In cycling cows and heifers:
Insert one CIDR 1.38 g into vagina for 7 days.
Inject a luteolytic dose of PGF2α
FTAI 56 hours after removal of the device.
In cycling and non-cycling cows and heifers:
Insert one CIDR 1.38 g into vagina for 7- 8 days.
Inject a dose of GnRH or analogue at CIDR 1.38 g insertion.
Inject a luteolytic dose of PGF2α
FTAI 56 hours after removal of the device, or
Inject GnRH or analogue 36 hours after CIDR 1.38 g removal and FTAI 16 to 20
hours later.
In non-cycling cows:
The following FTAI protocol should be used:
Insert one CIDR 1.38 g into vagina for 9 days.
Inject a luteolytic dose of PGF2α
AN: 03122/2024Page 5 of 8
Inject eCG at CIDR 1.38 g removal.
FTAI 56 hours after removal of the device, or inseminate within 12 hours following
first observed oestrus behaviour.
Administration:
A device applicator should be used for administration, following the procedure
described below:
1. Ensure that the applicator is clean and dipped in a non-irritant antiseptic solution
before use.
2. Wearing sterile disposable plastic gloves, fold the arms of the device and
load into the applicator. The arms of the device should protrude slightly from
the end of the applicator. Care should be taken to avoid unnecessary or
prolonged handling of the veterinary medicinal product to minimise transfer
of the active substance to the operator's gloves.
3. Apply a small quantity of obstetrical lubricant to the end of the loaded applicator.
4. Lift the tail and clean the vulva and perineum.
5. Gently insert the applicator into the vagina, first in a vertical direction and then
horizontally until some resistance is encountered.
6. Make sure the removal string is free, press the handle of the applicator and allow
the barrel to move back towards the handle. This releases the arms of the
device, which will then retain the device in the anterior vagina.
7. With the device correctly positioned, withdraw the applicator, leaving the removal
string hanging from the vulva.
8. The applicator should be cleaned and disinfected before being used on another
animal.
Removal:
The device may be removed by gently pulling on the string. On occasions the string
may not be visible from the outside of the animal, in such cases it may be located in the
posterior vagina using a gloved finger. Withdrawal of the device should not require
force. If any resistance is encountered a gloved hand should be used to ease removal.
If there is any difficulty in removal from the animal beyond that itemised above
veterinary advice must be sought.
The device is intended for single use only.

Do not use in cows or heifers, with abnormal or immature genital tracts, or with
genital infections.
Do not use in pregnant cattle.
Do not use within the first 35 days after calving.
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.

Cattle (cows and heifers):
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
vaginal discharge
, vulva irritation /
vaginal irritation
1
observed at removal of insert, this discharge generally clears between the time of
removal and insemination and has not been seen to affect conception rates following
treatment.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder <or its local representative> or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.

The progesterone treatment alone, according to dosage regimen proposed, is not
sufficient to induce oestrus and ovulation in all cycling females. Progesterone-based
breeding protocols are reproduction management tools and should not replace
adequate feeding and general health management. The choice of a specific protocol
should be based on the requirements of the individual herd and it is advisable to
examine cycling ovarian activity before using the progesterone treatment.
The response of cows and heifers to progesterone-based synchronisation protocols is
influenced by the physiological state at the time of treatment.
Responses to treatment can vary either across herds or across cows within herds.
However, the percentage of cows displaying oestrus within a given period is usually
greater than in untreated cows and the subsequent luteal phase is of normal duration.

Special precautions for safe use in the target species:
Animals in poor condition, whether from illness, inadequate nutrition, or other factors,
may respond poorly to treatment.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Progesterone is a potent steroid hormone and may cause adverse effects on the
reproductive system in cases of high or prolonged exposure. As adverse effects on
unborn children cannot be ruled out, pregnant women should avoid using this veterinary
medicinal product.
The veterinary medicinal product may cause skin and eye irritation as well as allergic
skin rashes.
Avoid accidental contact with the eyes. In case of accidental ocular exposure, flush the
eyes thoroughly with water.
AN: 03122/2024Page 3 of 8
Persons administering the veterinary medicinal product should avoid contact with the
silicone section; pregnant women should completely avoid handling the veterinary
medicinal product.
The device should be inserted using the veterinary medicinal product specific
applicator.
Personal protective equipment consisting of gloves should be worn when handling the
veterinary medicinal product during insertion and removal.
Ensure correct administration; including use of a non-irritant antiseptic and lubrication
(see section 3.9).
Wash hands and exposed skin with soap and water after use.
Do not eat, drink or smoke while handling the veterinary medicinal product.
Special precautions for the protection of the environment:
Not applicable.

None known.

Do not store above 30 °C.

Meat and offal: zero days.
Milk: zero hours.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.